{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:24:48Z","timestamp":1772166288973,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ck0106210h0003, 19ck0106485h001"],"award-info":[{"award-number":["18ck0106210h0003, 19ck0106485h001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund","award":["31-A-17"],"award-info":[{"award-number":["31-A-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The purpose of this study was to determine the potential of escalated dose radiation (EDR) robust intensity-modulated proton radiotherapy (ro-IMPT) in reducing GI toxicity risk in locally advanced unresectable pancreatic cancer (LAUPC) of the head in term of normal tissue complication probability (NTCP) predictive model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For 9 patients, intensity-modulated radiotherapy (IMRT) was compared with ro-IMPT. For all plans, the prescription dose was 59.4GyE (Gray equivalent) in 33 fractions with an equivalent organ at risk (OAR) constraints. Physical dose distribution was evaluated. GI toxicity risk for different endpoints was estimated using published NTCP Lyman Kutcher Burman (LKB) models for stomach, duodenum, small bowel, and combine stomach and duodenum (Stoduo). A Wilcoxon signed-rank test was used for dosimetry parameters and NTCP values comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      The dosimetric results have shown that, with similar target coverage, ro-IMPT achieves a significant dose-volume reduction in the stomach, small bowel, and stoduo in low to high dose range in comparison to IMRT. NTCP evaluation for the endpoint gastric bleeding of stomach (10.55% vs. 13.97%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007), duodenum (1.87% vs. 5.02%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004), and stoduo (5.67% vs. 7.81%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008) suggest reduced toxicity by ro-IMPT compared to IMRT. \u2206NTCP\n                      <jats:sub>IMRT \u2013 ro-IMPT<\/jats:sub>\n                      (using parameter from Pan et al. for gastric bleed) of \u22655 to &lt;\u200910% was seen in 3 patients (33%) for stomach and 2 patients (22%) for stoduo. An overall GI toxicity relative risk (NTCP\n                      <jats:sub>ro-IMPT<\/jats:sub>\n                      \/NTCP\n                      <jats:sub>IMRT<\/jats:sub>\n                      ) reduction was noted (0.16\u20130.81) for all GI-OARs except for duodenum (&gt;\u20091) with endpoint grade\u2009\u2265\u20093 GI toxicity (using parameters from Holyoake et al.).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With similar target coverage and better conformity, ro-IMPT has the potential to substantially reduce the risk of GI toxicity compared to IMRT in EDR of LAUPC of the head. This result needs to be further evaluated in future clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-020-01592-6","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T08:02:48Z","timestamp":1592812968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head"],"prefix":"10.1186","volume":"15","author":[{"given":"Vijay P.","family":"Raturi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Rachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenobu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaki","family":"Ariji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"issue":"6","key":"1592_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"1592_CR2","doi-asserted-by":"publisher","unstructured":"Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(04)15841-8.","DOI":"10.1016\/S0140-6736(04)15841-8"},{"issue":"5","key":"1592_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/COC.0b013e3181e9c103","volume":"34","author":"HR Cardenes","year":"2011","unstructured":"Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier oncology group study. Am J Clin Oncol. 2011;34(5):460\u20135. https:\/\/doi.org\/10.1097\/COC.0b013e3181e9c103.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1592_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.radonc.2014.11.043","volume":"114","author":"M-I Bittner","year":"2015","unstructured":"Bittner M-I, Grosu A-L, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review. Radiother Oncol. 2015;114(1):117\u201321. https:\/\/doi.org\/10.1016\/j.radonc.2014.11.043.","journal-title":"Radiother Oncol"},{"issue":"8","key":"1592_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1245\/s10434-010-1019-y","volume":"17","author":"F Polistina","year":"2010","unstructured":"Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010;17(8):2092\u2013101. https:\/\/doi.org\/10.1245\/s10434-010-1019-y.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1592_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","volume":"84","author":"E Ben-Josef","year":"2012","unstructured":"Ben-Josef E, Schipper M, Francis IR, et al. A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1166\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.02.051.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1592_CR7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00535-013-0857-3","volume":"49","author":"K Takatori","year":"2014","unstructured":"Takatori K, Terashima K, Yoshida R, et al. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2014;49(6):1074\u201380. https:\/\/doi.org\/10.1007\/s00535-013-0857-3.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1592_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","volume":"103","author":"K Terashima","year":"2012","unstructured":"Terashima K, Demizu Y, Hashimoto N, et al. A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012;103(1):25\u201331. https:\/\/doi.org\/10.1016\/j.radonc.2011.12.029.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1592_CR9","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/J.IJROBP.2012.09.035","volume":"85","author":"P Kelly","year":"2013","unstructured":"Kelly P, Das P, Pinnix CC, et al. Duodenal toxicity after fractionated Chemoradiation for Unresectable pancreatic Cancer. Int J Radiat Oncol. 2013;85(3):e143\u20139. https:\/\/doi.org\/10.1016\/J.IJROBP.2012.09.035.","journal-title":"Int J Radiat Oncol."},{"issue":"3","key":"1592_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3109\/0284186X.2012.762997","volume":"52","author":"RC Nichols","year":"2013","unstructured":"Nichols RC, George TJ, Zaiden RA, et al. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol (Madr). 2013;52(3):498\u2013505. https:\/\/doi.org\/10.3109\/0284186X.2012.762997.","journal-title":"Acta Oncol (Madr)."},{"issue":"3","key":"1592_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.14338\/ijpt.14-00006.1","volume":"1","author":"S Sachsman","year":"2014","unstructured":"Sachsman S, Nichols RC, Morris CG, et al. Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma. Int J Part Ther. 2014;1(3):692\u2013701. https:\/\/doi.org\/10.14338\/ijpt.14-00006.1.","journal-title":"Int J Part Ther"},{"issue":"3","key":"1592_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.semradonc.2018.02.009","volume":"28","author":"K Langen","year":"2018","unstructured":"Langen K, Zhu M. Concepts of PTV and robustness in passively scattered and pencil beam scanning proton therapy. Semin Radiat Oncol. 2018;28(3):248\u201355. https:\/\/doi.org\/10.1016\/j.semradonc.2018.02.009.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"1592_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-8-145","volume":"8","author":"M Stuschke","year":"2013","unstructured":"Stuschke M, Kaiser A, Jawad JA, P\u00f6ttgen C, Levegr\u00fcn S, Farr J. Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck regi. Radiat Oncol. 2013;8(1):1\u20135. https:\/\/doi.org\/10.1186\/1748-717X-8-145.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1592_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13014-018-1165-0","volume":"13","author":"S Stefanowicz","year":"2018","unstructured":"Stefanowicz S, St\u00fctzer K, Zschaeck S, Jakobi A, Troost EGC. Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer. Radiat Oncol. 2018;13(1):228. https:\/\/doi.org\/10.1186\/s13014-018-1165-0.","journal-title":"Radiat Oncol"},{"issue":"2","key":"1592_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.radonc.2009.04.015","volume":"92","author":"M Bouchard","year":"2009","unstructured":"Bouchard M, Amos RA, Briere TM, Beddar S, Crane CH. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol. 2009;92(2):238\u201343. https:\/\/doi.org\/10.1016\/j.radonc.2009.04.015.","journal-title":"Radiother Oncol"},{"issue":"8Part1","key":"1592_CR16","doi-asserted-by":"publisher","first-page":"081711","DOI":"10.1118\/1.4887797","volume":"41","author":"RF Thompson","year":"2014","unstructured":"Thompson RF, Mayekar SU, Zhai H, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41(8Part1):081711. https:\/\/doi.org\/10.1118\/1.4887797.","journal-title":"Med Phys"},{"issue":"3","key":"1592_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","volume":"107","author":"JA Langendijk","year":"2013","unstructured":"Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107(3):267\u201373. https:\/\/doi.org\/10.1016\/j.radonc.2013.05.007.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1592_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","volume":"68","author":"JD Murphy","year":"2007","unstructured":"Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for Unresectable pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):801\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.12.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"1592_CR19","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1200\/JCO.2001.19.22.4202","volume":"19","author":"CJ McGinn","year":"2001","unstructured":"McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19(22):4202\u20138. https:\/\/doi.org\/10.1200\/JCO.2001.19.22.4202.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1592_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0360-3016(99)00056-5","volume":"44","author":"JW Wong","year":"1999","unstructured":"Wong JW, Sharpe MB, Jaffray DA, et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 1999;44(4):911\u20139. https:\/\/doi.org\/10.1016\/S0360-3016(99)00056-5.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1592_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijrobp.2011.12.026","volume":"84","author":"A Nakamura","year":"2012","unstructured":"Nakamura A, Shibuya K, Matsuo Y, et al. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84(2):369\u201375. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1592_CR22","doi-asserted-by":"crossref","unstructured":"Uzawa A, Ando K, Furusawa Y, et al. Biological Intercomparison Using Gut Crypt Survivals for Proton and Carbon-Ion Beams. 2007;48 http:\/\/jrr.jstage.jst.go.jp. Accessed June 12, 2019.","DOI":"10.1269\/jrr.48.A75"},{"issue":"4","key":"1592_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.21037\/jgo.2018.03.14","volume":"9","author":"M Chuong","year":"2018","unstructured":"Chuong M, Badiyan SN, Yam M, et al. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. J Gastrointest Oncol. 2018;9(4):687\u201393. https:\/\/doi.org\/10.21037\/jgo.2018.03.14.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"1592_CR24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/J.IJROBP.2011.09.022","volume":"83","author":"J Huang","year":"2012","unstructured":"Huang J, Robertson JM, Ye H, Margolis J, Nadeau L, Yan D. Dose\u2013volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol. 2012;83(4):1120\u20135. https:\/\/doi.org\/10.1016\/J.IJROBP.2011.09.022.","journal-title":"Int J Radiat Oncol."},{"issue":"1","key":"1592_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijrobp.2011.05.045","volume":"83","author":"RC Nichols","year":"2012","unstructured":"Nichols RC, Huh SN, Prado KL, et al. Protons offer reduced Normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head Cancer. Int J Radiat Oncol. 2012;83(1):158\u201363. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.045.","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"1592_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0360-3016(91)90172-Z","volume":"21","author":"C Burman","year":"1991","unstructured":"Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21(1):123\u201335. https:\/\/doi.org\/10.1016\/0360-3016(91)90172-Z.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1592_CR27","doi-asserted-by":"publisher","unstructured":"Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8. https:\/\/doi.org\/10.2307\/3583506.","DOI":"10.2307\/3583506"},{"issue":"2","key":"1592_CR28","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/s0360-3016(03)01031-9","volume":"57","author":"C Pan","year":"2003","unstructured":"Pan C, Dawson L, McGinn C, Lawrence T, Ten Haken R. Analysis of radiation-induced gastric and duodenal bleeds using the Lyman-Kutcher-Burman model. Int J Radiat Oncol. 2003;57(2):S217\u20138. https:\/\/doi.org\/10.1016\/s0360-3016(03)01031-9.","journal-title":"Int J Radiat Oncol."},{"issue":"3","key":"1592_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.radonc.2017.04.024","volume":"123","author":"DLP Holyoake","year":"2017","unstructured":"Holyoake DLP, Aznar M, Mukherjee S, Partridge M, Hawkins MA. Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data. Radiother Oncol. 2017;123(3):431\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2017.04.024.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1592_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejmp.2015.10.091","volume":"32","author":"JH Chang","year":"2016","unstructured":"Chang JH, Gehrke C, Prabhakar R, et al. RADBIOMOD: a simple program for utilising biological modelling in radiotherapy plan evaluation. Phys Medica. 2016;32(1):248\u201354. https:\/\/doi.org\/10.1016\/j.ejmp.2015.10.091.","journal-title":"Phys Medica"},{"issue":"3","key":"1592_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.adro.2018.04.003","volume":"3","author":"KR Jethwa","year":"2018","unstructured":"Jethwa KR, Tryggestad EJ, Whitaker TJ, et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol. 2018;3(3):314\u201321. https:\/\/doi.org\/10.1016\/j.adro.2018.04.003.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"1592_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21037\/jgo.2019.06.08","volume":"11","author":"C Beltran","year":"2020","unstructured":"Beltran C, Schultz HL, Anand A, Merrell K. Radiation biology considerations of proton therapy for gastrointestinal cancers. J Gastrointest Oncol. 2020;11(1):225\u201330. https:\/\/doi.org\/10.21037\/jgo.2019.06.08.","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"1592_CR33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1080\/0284186X.2017.1371325","volume":"56","author":"H Paganetti","year":"2017","unstructured":"Paganetti H. Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in \u03b1\/\u03b2. Acta Oncol (Madr). 2017;56(11):1379\u201386. https:\/\/doi.org\/10.1080\/0284186X.2017.1371325.","journal-title":"Acta Oncol (Madr)"},{"issue":"2","key":"1592_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0360-3016(02)02754-2","volume":"53","author":"H Paganetti","year":"2002","unstructured":"Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53(2):407\u201321. https:\/\/doi.org\/10.1016\/S0360-3016(02)02754-2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1592_CR35","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","volume":"76","author":"BD Kavanagh","year":"2010","unstructured":"Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose\u2013volume effects in the stomach and small bowel. Int J Radiat Oncol. 2010;76(3):S101\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.05.071.","journal-title":"Int J Radiat Oncol."},{"key":"1592_CR36","first-page":"140","volume-title":"Joint Conference of the SSRMP, DGMP, \u00d6GMP","author":"K St\u00fctzer","year":"2014","unstructured":"St\u00fctzer K, Jakobi A, Haase R, et al. Characterization of deformation vector fields for the registration of dose distribution in adaptive treatment planning and sequential boost protocols. In: Joint Conference of the SSRMP, DGMP, \u00d6GMP; 2014. p. 140\u20131. ISBN: 987-3-9816508-5-3."},{"key":"1592_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.radonc.2019.08.005","volume":"141","author":"EW Korevaar","year":"2019","unstructured":"Korevaar EW, Habraken SJM, Scandurra D, et al. Practical robustness evaluation in radiotherapy \u2013 a photon and proton-proof alternative to PTV-based plan evaluation. Radiother Oncol. 2019;141:267\u201374. https:\/\/doi.org\/10.1016\/j.radonc.2019.08.005.","journal-title":"Radiother Oncol"},{"issue":"5","key":"1592_CR38","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ijrobp.2014.11.021","volume":"91","author":"H Paganetti","year":"2015","unstructured":"Paganetti H. Relating proton treatments to photon treatments via the relative biological effectiveness - should we revise current clinical practice? Int J Radiat Oncol Biol Phys. 2015;91(5):892\u20134. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.11.021.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01592-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01592-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01592-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T19:33:55Z","timestamp":1624304035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01592-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01592-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-26367\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by National Cancer Center Hospital East (NCCHE) Institute Research Ethics Committee (Reference number: 2017\u2013440).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}